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Abstract
 
Uteroglobin (UG) is an antiinflammatory protein secreted by the epithelial lining of all organs
communicating with the external environment. We reported previously that UG-knockout
mice manifest exaggerated inflammatory response to allergen, characterized by increased eotaxin
and Th2 cytokine gene expression, and eosinophil infiltration in the lungs. In this study, we
uncovered that the airway epithelia of these mice also express high levels of cyclooxygenase
(COX)-2, a key enzyme for the production of proinflammatory lipid mediators, and the
bronchoalveolar lavage fluid (BALF) contain elevated levels of prostaglandin D
 
2
 
. These effects
are abrogated by recombinant UG treatment. Although it has been reported that prostaglandin
D
 
2
 
 mediates allergic inflammation via its receptor, DP, neither the molecular mechanism(s)
of DP signaling nor the mechanism by which UG suppresses DP-mediated inflammatory
response are clearly understood. Here we report that DP signaling is mediated via p38 mitogen–
activated protein kinase, p44/42 mitogen–activated protein kinase, and protein kinase C
pathways in a cell type–specific manner leading to nuclear factor–
 
 
 
B activation stimulating
COX-2 gene expression. Further, we found that recombinant UG blocks DP-mediated
nuclear factor–
 
 
 
B activation and suppresses COX-2 gene expression. We propose that UG is
an essential component of a novel innate homeostatic mechanism in the mammalian airways
to repress allergen-induced inflammatory responses.
Key words: allergic airway inﬂammation • uteroglobin • Th2 cytokines • eosinophils • 
secretoglobin
 
Introduction
 
Allergic inflammatory disorders result from a complex
interplay of genetic and environmental factors. Even
though the incidence of these disorders is on the rise
throughout the industrialized world, the majority of the
population manages to avert allergic inflammatory diseases.
Thus, it appears that homeostatic mechanisms may exist to
repress allergen-mediated inflammatory responses.
Uteroglobin (UG) is a steroid-inducible, low molecular
weight, multifunctional, secreted protein with antiinflam-
matory/antichemotactic properties (for review see reference
1). It is the founding member of a newly designated
 
Secretoglobin
 
 superfamily of proteins (2), constitutively
expressed by the epithelial lining of all organs that com-
municate with the external environment. Structurally, UG
is a homodimer in which the 70-amino acid subunits are
covalently linked in antiparallel orientation by two inter-
chain disulfide bridges forming a central hydrophobic cav-
ity (3, 4). It has been suggested that this central cavity is
capable of binding hydrophobic ligands such as steroid
hormones, polychlorinated biphenyls, and retinol. The physi-
ological importance of this property of UG remains unclear.
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 AA, arachidonic acid; BALF, bronchoalveolar
lavage fluid; COX, cyclooxygenase; EMSA, electrophoretic mobility shift
analysis
 
; 
 
MAPK, mitogen-activated protein kinase; MG, myoglobin;
OVA, ovalbumin; PGD
 
2
 
, prostaglandin D
 
2
 
; PKC, protein kinase C; rUG,
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We reported previously that OVA immunization and
challenge of UG-KO mice (5) cause highly exaggerated al-
lergic response characterized by increased expression of
Th2 cytokines, eotaxin, and eosinophil infiltration in the
lungs (6). This suggests that UG may have a protective role
against allergen-induced inflammatory response. However,
the molecular mechanism(s) by which UG prevents aller-
gen-induced inflammatory response remains unclear.
It is generally accepted that mast cells and other cell types
in the lungs orchestrate allergic inflammation through the
production of various cytokines and lipid mediators of in-
flammation such as prostaglandin D
 
2
 
 (PGD
 
2
 
) (7–11). Previ-
ous studies have shown that antigen/allergen challenge
stimulates the release of arachidonic acid (AA) from mem-
brane phospholipids by cytosolic phospholipase A
 
2
 
 catalysis
(12). Moreover, it has been reported that PGD
 
2
 
 reinforces
low dose antigen-stimulated Th2-type inflammatory re-
sponses via expression of macrophage-derived chemokines
(13). More recently, it has been demonstrated that targeted
overexpression of PGD
 
2
 
 synthase gene in the lungs of
transgenic mice causes elevated levels of Th2 cytokines and
eosinophil infiltration (14). Prostaglandins are produced
from oxidation of arachidonic acid by cyclooxygenases
(COX), also known as prostaglandin H synthase (15). Be-
tween the two isoforms of COX, COX-1 is constitutively
expressed, whereas COX-2 is agonist inducible and plays
critical roles in the production of proinflammatory lipid
mediators (for review see reference 16). Moreover, it has
been reported that: (a) the expression of COX-2, a critical
enzyme for the production of proinflammatory lipid medi-
ators in the respiratory system, is elevated in patients with
allergic inflammation and asthma (17); (b) bronchoalveolar
lavage fluids (BALFs), after acute antigen challenge (7) and
those from patients with allergic asthma, contain high levels
of PGD
 
2
 
; (c) mice in which PGD
 
2
 
 receptor, DP, is dis-
rupted by gene targeting are refractory to developing aller-
gen-induced airway inflammation (18); and (d) treatment
of mice with a synthetic DP antagonist prevents allergic in-
flammation (19). Together, these results suggest that aller-
gen-induced activation stimulates the release of PGD
 
2
 
,
which mediates inflammation via DP signaling. However,
the molecular mechanism(s) of DP signaling leading to
allergic inflammatory response and the mechanism(s) by
which UG represses allergen-induced inflammatory re-
sponses, until now, remained obscure.
To understand the molecular mechanism(s) of the ex-
aggerated allergic response in UG-KO mice, we first
performed detailed analyses of inflammatory response in
OVA-sensitized and OVA-challenged UG-KO mice. We
uncovered that in addition to the elevated expression of
eotaxin, Th2 cytokines, and pulmonary eosinophil infil-
tration reported previously (6), the UG-KO mice also
manifest elevated levels of PGD
 
2
 
 in the BALF and show
increased COX-2 gene expression in the lungs. More sig-
nificantly, treatment of these mice with purified recombi-
nant UG (rUG) markedly inhibits these responses. Using
representative cell lines from the mammalian respiratory
system, we conducted experiments to understand: (a) the
molecular mechanism(s) of DP signaling and (b) the mech-
anism by which UG suppresses DP-mediated inflammatory
response. The results of these studies show that DP signal-
ing is mediated via p38 mitogen-activated protein kinase
(MAPK), p44/42 MAPK, and protein kinase C (PKC)
pathways in a cell type–specific manner leading to the acti-
vation of nuclear factor (NF)–
 
 
 
B. Activation of NF-
 
 
 
B
then stimulates the expression of COX-2, an agonist (aller-
gen)-inducible enzyme that is critical for the production of
inflammatory lipid mediators. Most importantly, we found
that UG binds PGD
 
2
 
, blocks DP signaling, inhibits NF-
 
 
 
B
activation, and consequently suppresses COX-2 gene ex-
pression. Our results, for the first time, demonstrate that at
least one of the mechanisms by which DP signaling medi-
ates allergic inflammatory response is by activating NF-
 
 
 
B
that stimulates COX-2 expression. We propose that UG is
a critical component of an innate homeostatic mechanism
to prevent inadvertent stimulation of allergen-induced,
DP-mediated inflammatory response.
 
Materials and Methods
 
Cell Lines and Mice.
 
The human bronchial smooth muscle
(BSM-2146) and human alveolar type II (A549) cells were from
Clonetics-BioWhittaker, Inc. The NIH-3T3 cells were from
American Type Culture Collection. UG-KO mice were gener-
ated as described previously (5). Both UG-KO and WT mice
were maintained under germ-free conditions, and all experiments
were performed according to an institutionally approved animal
use protocol.
 
Production and Purification of rUG.
 
The production and purifi-
cation of rUG have been described previously (20, 21).
 
Sensitization and Antigen Challenge of WT and UG-KO Mice.
 
UG-KO and their WT littermates were injected i.p. with 10 
 
 
 
g
of OVA (grade V; Sigma-Aldrich) in 0.2 ml alum on day 0 and
14. The sensitized mice were challenged with OVA on day 21 as
described previously (6, 14).
 
Lung Lavage, Tissue Fixation, Histology, and Immunofluores-
cence.
 
The mice were killed 24 h after the OVA challenge, and
BALF was collected in 1 ml of PBS as reported previously (6, 14).
Total leukocyte counts and numbers of each cell type per millili-
ter of BALF were determined as reported (6, 14). Lung tissues
were fixed in 4% paraformaldehyde and embedded in paraffin
blocks. Tissue sections were stained with Verfuerth-Luna by
American Histolabs, Inc. The stained slides were examined by us-
ing a Carl Zeiss MicroImaging, Inc. Axiophot Microscope, and
digital photomicrographs were recorded.
 
RNA Isolation and Northern Blot Analyses.
 
Total RNAs from
whole lungs were isolated using either Trizol (Invitrogen) or
RNAzol B (Teltest Inc.) following the suppliers’ protocol. Total
RNA (25–40 
 
 
 
g) loaded in each lane were resolved by electro-
phoresis on 1.5% formaldehyde-agarose gels, and RNAs were
transferred to Hybond N
 
 
 
 (Amersham Biosciences), cross-linked,
and hybridized with [
 
 
 
32
 
P]-dCTP-labeled cDNA probes at 68
 
 
 
C.
The probes were generated by RT-PCR using gene-specific
primers (Table S1, available at http://www.jem.org/cgi/content/
full/jem.20031666/DC1) and sequence was conformed by DNA
sequencing. RNA loading was standardized by hybridizing the
blots with GAPDH or 
 
 
 
-actin probes (5). 
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Cytokine and Eotaxin-mRNA Determination by Real-Time Quan-
titative RT-PCR Analyses.
 
The total RNA (1 
 
 
 
g) from the
lungs was reverse transcribed using SuperScript III First-Strand
Synthesis System for RT-PCR (Invitrogen). Real-time quantita-
tive RT-PCR was performed using ABI Prism 7000 Sequence
Detection System (Applied Biosystems) with cDNA equivalent
to 40 ng of total RNA and SYBR Green PCR Master Mix (Ap-
plied Biosystems) following the manufacturer’s protocol. The fol-
lowing PCR conditions were used: denaturation at 95
 
 
 
C for 10
min followed by 50 cycles of amplification at 94
 
 
 
C for 15 s and
60
 
 
 
C for 1 min. The primers used for IL-4, IL-5, IL-13, eotaxin,
and 
 
 
 
-actin are presented in Table S1. The data from each PCR
run was analyzed using ABI Prism Software version 1.01 (Ap-
plied Biosystems). The final data were normalized to 
 
 
 
-actin and
presented as fold induction compared with the expression level in
WT mice. Quantitation was performed using three independent
total RNA samples for each treatment group.
 
Semiquantitative RT-PCR Analyses for DP- and UG-mRNA Ex-
pression.
 
The total RNA (1 
 
 
 
g) was reverse transcribed, and
semiquantitative PCR was performed to amplify target fragments
of cDNA with 5 
 
 
 
l of reverse transcription product using human
and mouse DP- and UG-specific sense and antisense primers
(Table S2, available at http://www.jem.org/cgi/content/full/
jem.20031666/DC1). The primers for GAPDH are as reported
previously (6). The following PCR conditions were used: dena-
turation at 95
 
 
 
C for 1 min followed by 30 cycles of amplification
at 95
 
 
 
C for 30 s, 60
 
 
 
C for 50 s, 68
 
 
 
C for 3 min, and a final incu-
bation at 68
 
 
 
C for 10 min.
 
Cell Culture and Treatment.
 
BSM-2146 cells were grown in
their specified SmGM-2 medium (Clonetics). The NIH-3T3
cells were grown in DMEM at 37
 
 
 
C with 5% CO
 
2
 
 as described
above. Cells were gown to 70–80% confluence before treating
with various effectors (PGD
 
2
 
, rUG, kinase inhibitors, etc.),
washed once with OptiMem-1 containing 2.5% FBS and then
treated with the indicated effectors for the indicated period at
37
 
 
 
C with 5% CO
 
2
 
. The extracellular signal-regulated kinase
pathway–specific inhibitor (PD98059) and the p38 MAPK path-
way–specific inhibitor (SB203580) were dissolved in DMSO and
then added to the OptiMEM-1 to obtain the indicated final con-
centration. Protein kinase C inhibitor, bisindolyl maleimide III
(BMIII), was dissolved in water and added to the medium to ob-
tain the desired final concentrations. Cells were pretreated for 15
min with these inhibitors or with DMSO alone (control) before
addition of PGD
 
2
 
 (up to 50 
 
 
 
M) or as indicated. BSM-2146 cells
were incubated for 3 h, and NIH-3T3 cells were incubated for
2 h at 37
 
 
 
C with 5% CO
 
2
 
.
 
3
 
H-PGD
 
2
 
–binding Assay.
 
Cells were grown to 70–80% con-
fluence in their recommended growth medium in 6-well cell
culture plates, washed once with OptiMEM-1 without serum,
and then incubated with 10 nM 
 
3
 
H-PGD
 
2
 
 in the absence and
presence of varying concentrations (1 nM–5 
 
 
 
M) of PGD
 
2
 
 for 30
min at 4
 
 
 
C in 3 ml of OptiMEM without serum. Unbound 
 
3
 
H-
PGD
 
2
 
 was removed by washing the cells three times with PBS.
Cells were then lysed with lysis buffer, and 300 
 
 
 
l of the cell ly-
sate was applied on a strip of 3-mm Whatman filter paper in a
scintillation vial, dried at room temperature, and counted in a
scintillation counter.
 
Transfection of Cells with DP Antisense Oligonucleotides.
 
A
phosphorothioate DP antisense oligo (5
 
 
 
-GTGACGGCATTG-
CACGAGAAGG-3
 
 
 
) was designed to inhibit DP expression. As
a control, the corresponding sense-oligo (5
 
 
 
-CCTTCTCGTG-
CAATGCCGTCAC-3
 
 
 
) was used. When the cells reached 30–
40% confluence, they were rinsed once with serum-free Opti-
MEM I medium. The oligonucleotides were then delivered to
the cells by Oligofectamine™
 
 
 
Reagent (Invitrogen) according to
the manufacturer’s instructions. After 28 h, the cells were stimu-
lated with 1 
 
 
 
M PGD
 
2
 
, and total proteins were isolated. The rel-
ative levels of COX-2 protein were estimated by Western blot
analysis.
 
Western Blot Analyses.
 
For detection of the phosphorylated
proteins, cell lysates were prepared in presence of protease and
protein phosphatase inhibitors. Total protein (40 
 
 
 
g) from each
sample was resolved by electrophoresis using 7.5% or 12% SDS-
polyacrylamide gels under reducing conditions and electrotrans-
ferred to polyvinylidene fluoride membrane (Immobilon P; Mil-
lipore Corporation). Immunoblot analysis was performed using
either goat or rabbit polyclonal anti–COX-2 (Santa Cruz Biotech
Inc.)/anti–phospho p38-MAPK/anti–phospho p44/42 antibodies
(Cell Signaling), respectively. Horseradish peroxidase–conjugated
anti–goat or anti–rabbit IgGs were used as the second antibody.
Chemiluminescent detection was performed by using ECL sys-
tem (Amersham Biosciences) according to the manufacturer’s
protocol. Total protein loading standard, 
 
 
 
-actin, was detected
using Actin (Ab-1) Kit (Oncogene Research Products) according
to the protocol of the supplier.
 
Blocking DP-mediated COX-2 Expression by DP Monoclonal An-
tibody Treatment of the Cells.
 
The NIH-3T3 cells were grown to
70–80% confluence. The cells were washed three times with se-
rum-free OptiMEM and incubated with DP monoclonal anti-
body (Abcam, UK) in varying dilutions at room temperature
with gentle agitation. After washing the cells with serum-free
OptiMEM, the cells were stimulated with 1 
 
 
 
M PGD
 
2
 
 for 2 h.
Total RNA was isolated and analyzed for COX-2 mRNA ex-
pression by real-time quantitative RT-PCR (22) using the mouse
COX-2–specific primers (Table S2). Fold COX-2 expression
levels were normalized to18S rRNA (for 18S primers see Table
S2) and compared with the average values in untreated control
cells. All determinations were performed in triplicates, and each
experiment was repeated at least twice. COX-2 protein expres-
sion was determined by Western blot analysis.
 
Nuclear Extract Preparation and Electrophoretic Mobility Shift As-
say.
 
Cells were treated with PGD
 
2
 
 (50 
 
 
 
M) in the presence and
absence of rUG (150 nM). Nuclear extracts were prepared using
commercially available buffers (GENEKA Biotech Inc.) using sup-
plier’s protocol. Electrophoretic mobility shift analyses (EMSAs)
were performed using the nuclear extracts (20 
 
 
 
g protein) on a non-
denaturing 5% polyacrylamide gel with the following oligonucle-
otides: for human cell extracts, hNF
 
 
 
Bwt, 5
 
 
 
-AGTTGAGGGG-
ACTTTCCCAGGC-3
 
 
 
; hNF
 
 
 
BMu, 5
 
 
 
-AGTTGAG
 
AT
 
GACT-
 
CG
 
CCCAGGC-3
 
 
 
; for mouse cell extracts, mNF
 
 
 
Bwt, 5
 
 
 
-
GAGGGTGAGGGGATTCCCTTAGTTAGGAC-3
 
 
 
; mNF
 
 
 
-
Bmu, 5
 
 
 
-GAGAGGTGAG
 
AT
 
GAT
 
AG
 
CCTTAGTTAGGAC-3
 
 
 
;
mNF-IL6, 5
 
 
 
-CTGCCGCTGCGGTTCTTGCGCAACTCACT-
3
 
 
 
; mAP1, 5
 
 
 
-AAAGACAGAGTCACCACTAATT-3
 
 
 
. NF-
 
 
 
B
double-stranded oligonucleotides were generated by annealing sense
and antisense oligonucleotides without and with mutations (bold).
Specificity of protein–DNA complexes was verified either by com-
peting with cold NF-
 
 
 
Bwt/NF-
 
 BMu oligos or by immunoreac-
tivity with polyclonal antibodies specific for p65/p50 subunits of
NF- B.
Statistical Analysis. Data were analyzed by using GraphPad
Prism software (version 3.03). Student’s t test was used to deter-
mine the significant differences between the means; p-values of
 0.05 were considered as statistically significant.Uteroglobin Represses DP-mediated Inflammation 1320
Results
UG Inhibits Th2 Cytokine Expression in Allergen-sensitized
and -challenged UG-KO Mice. We reported previously that
UG-KO mice, sensitized and challenged with OVA, mani-
fest exaggerated allergic response characterized by elevated
eotaxin and Th2 cytokine expression and an increased
number of eosinophils in BALF (6). In this study, we ex-
amined the effects of rUG on these parameters. We first
treated the OVA-sensitized UG-KO mice with rUG before
OVA challenge and determined the expression of eotaxin
and representative Th2 cytokine mRNAs by real-time
quantitative RT-PCR. Our results confirm that OVA sen-
sitization and challenge increase the level of these mRNAs
in the lungs of UG-KO mice (Fig. 1 A) as reported previ-
ously (6). More importantly, we demonstrate that rUG
treatment of OVA-sensitized UG-KO mice before OVA
challenge inhibits the expression of IL-4 (Fig. 1 A, i), IL-5
(Fig. 1 A, ii), IL-13 (Fig. 1 A, iii), and eotaxin (Fig. 1 A, iv),
all of which are recognized markers of allergic inflamma-
tory response. The reduced level of inflammatory response
in the lungs of OVA-sensitized and challenged WT mice
may be due to the stimulation of UG expression in re-
sponse to increased levels of Th2 cytokines. This hypothesis
is at least partially supported by the fact that IL-13 treat-
ment stimulates UG production in rat lungs (23). There-
fore, we analyzed UG mRNA and UG protein in the lungs
of OVA-sensitized and challenged WT mice by semiquan-
titative RT-PCR and immunofluorescence, respectively.
The results show that OVA sensitization and challenge of
WT littermates of UG-KO mice expressed higher levels of
Figure 1. UG Inhibits proinflammatory cytokine
expression and eosinophil infiltration. (A) The
expression of IL-4 (i), IL-5 (ii), IL-13 (iii), and
eotaxin (iv) mRNA was determined by real-time
quantitative RT-PCR using total RNA from the
lungs of PBS-treated WT mice (bar 1), OVA-
sensitized and -challenged WT mice (bar 2), UG-
KO mice (bar 3), OVA-sensitized and -challenged
UG-KO mice without rUG treatment (bar 4), and
OVA-sensitized UG-KO mice that were pretreated
with rUG (250  g of rUG in 200  l PBS adminis-
tered i.v.) 30 min before OVA challenge (bar 5).
Asterisks indicate significance at P   0.05. (B) UG-
mRNA expression in the lungs of PBS-challenged
WT and OVA-sensitized and -challenged WT
mice by semiquantitative RT-PCR. (C) UG protein
expression (immunofluorescence) in bronchiolar
epithelial cells of WT mouse challenged with PBS
(left) or sensitized and challenged with OVA
(right). (D) Total cell counts and number of indi-
vidual leukocytes per milliliter of BALF from PBS
(control) and OVA-sensitized and -challenged WT
(left) and UG-KO (right) mice and the results from
OVA-sensitized and challenged (middle) and
OVA-sensitized UG-KO mice treated with rUG
before OVA challenge (extreme right). Values are
expressed as the mean   SD (n   5 per treatment
group). E, eosinophil; N, neutrophil; L, lympho-
cyte; M, monocyte. (E) Eosinophil infiltration in
nonsensitized and unchallenged WT control (frame
1); nonsensitized and unchallenged UG-KO control
(frame 2); WT mouse sensitized and challenged with
OVA (frame 3); UG-KO mouse sensitized and
challenged with OVA (frame 4); UG-KO mouse
sensitized and treated with rUG before OVA chal-
lenge (frame 5). b, bronchiole. Magnification,  400.Mandal et al. 1321
UG mRNA (Fig. 1 B) and UG protein (Fig. 1 C) com-
pared with their nonsensitized and nonchallenged counter-
parts. These results raise the possibility that the observed
OVA-induced elevation of UG production in WT mouse
lungs is likely to be a homeostatic response to counteract
inadvertent stimulation of allergen-induced inflammation.
UG Inhibits Eosinophil Infiltration. We further deter-
mined the effects of rUG treatment on the infiltration of
various leukocytes including eosinophils in the BALFs of
these mice. Quantitation of each cell type in the BALF
show that although leukocytes were virtually undetectable
in control WT and UG-KO mice (Fig. 1 D); OVA sensiti-
zation and challenge caused an upward shift not only in the
total number of infiltrated cells but also in the cell types.
Most importantly, rUG treatment of OVA-sensitized UG-
KO mice before OVA challenge significantly inhibited the
number of eosinophils in BALF (Fig. 1 D). These results
demonstrate that UG is a potent inhibitor of allergen-
induced lung infiltration of leukocytes, especially eosinophils.
Histological analysis of the lungs of OVA-sensitized and
OVA-challenged UG-KO and WT mice for eosinophil in-
filtration show that eosinophils in the lungs of control WT
and UG-KO mice are barely detectable (Fig. 1 E, frames 1
and 2). In contrast, although only a slight increase in the
level of eosinophil infiltration was detectable in the lungs of
OVA-sensitized and -challenged WT mice (Fig. 1 E, frame
3), it was markedly elevated in those of the UG-KO mice
(Fig. 1 E, frame 4). Most importantly, when the OVA-sen-
sitized UG-KO mice were treated with rUG before OVA
challenge, it markedly inhibited eosinophil infiltration in
the lungs (Fig. 1 E, frame 5). These results demonstrate that
UG is a potent inhibitor of allergen-induced eosinophil in-
filtration in the lungs.
UG Inhibits Allergen-Induced Elevation of PGD2 Levels in
BALF. Elevated levels of PGD2 in the BALF of patients
with allergic asthma have been reported, and it has been
suggested that PGD2 is a potent chemoattractant for eo-
sinophils (11, 24). Thus, we sought to determine the level
Figure 2. UG inhibits COX-2 expression
induced by allergens in vivo and by PGD2 in
vitro. (A) Northern blot analysis of COX-2
mRNA expression in the lungs of control
WT (lane 1) and control UG-KO (lane 2),
OVA-sensitized and -challenged WT (lane
3), OVA-sensitized and -challenged UG-KO
(lane 4), and OVA-sensitized and rUG-
treated before OVA challenge of UG-KO
(lane 5) mice. (B) COX-2 immunofluores-
cence in representative control WT (frame
1) and control UG-KO (frame 2) mice; WT
mouse sensitized and challenged with OVA
(frame 3); UG-KO mouse sensitized and
challenged with OVA (frame 4); UG-KO
mouse  sensitized and treated with rUG
before OVA challenge (frame 5). b, bron-
chiole. Magnification,  400. Time-course
of PGD2-induced COX-2 mRNA expres-
sion in BSM-2146 (C) and NIH-3T3 (D)
cells. Dose–response of PGD2-induced
stimulation of COX-2 mRNA expression
in BSM-2146 (E) and NIH-3T3 (F) cells.
Western blot analysis demonstrating PGD2-
induced COX-2 protein expression in
BSM-2146 (G) and NIH-3T3 cells (H).Uteroglobin Represses DP-mediated Inflammation 1322
of PGD2 in the BALF of OVA-sensitized and -challenged
UG-KO and WT mice. In addition, we studied the effects
of rUG treatment on PGD2 levels in BALF of OVA-sensi-
tized and challenged mice. The results (Table S3, available
at http://www.jem.org/cgi/content/full/jem.20031666/
DC1) show that a very low level of PGD2 is detectable in
the BALF of both UG-KO and WT control mice. In con-
trast, although PGD2 levels in BALF of OVA-sensitized
and challenged WT littermates increased moderately from
the baseline, higher levels of PGD2 were detected in those
of the OVA-sensitized and challenged UG-KO mice. Most
importantly, PGD2 levels in the BALF of OVA-sensitized
UG-KO mice that were treated with rUG before OVA
challenge were significantly reduced compared with those
without rUG pretreatment (Table S2). These results sug-
gest that UG inhibits allergen-induced elevation of PGD2
levels in the lungs.
UG Inhibits Allergen-induced Stimulation of COX-2 Gene
Expression In Vivo. COX-2 gene expression in the lungs
of allergic asthma patients is markedly elevated (17). Since
COX-2 is an agonist-inducible enzyme that catalyzes the
production of proinflammatory lipid mediators, we first an-
alyzed COX-2 gene expression in the lungs of nonsensi-
tized and unchallenged UG-KO and WT littermates. The
results show that a low level of COX-2 mRNA expression
is detectable in the lungs of the WT littermates (Fig. 2 A,
lane 1) and in those of the UG-KO (Fig. 2 A, lane 2) mice.
In contrast, although COX-2 mRNA expression in the
lungs of OVA-sensitized and challenged WT mice in-
creased slightly (Fig. 2 A, lane 3), the expression levels in
UG-KO mice were markedly elevated (Fig. 2 A, lane 4).
Most importantly, treatment of OVA-sensitized UG-KO
mice with rUG before OVA challenge showed an appre-
ciable inhibition of COX-2 mRNA expression (Fig. 2 A,
lane 5). We also found that compared with the intensity of
COX-2 immunofluorescence in the bronchioles of control
WT and UG-KO mice (Fig. 2 B, frames 1 and 2) immuno-
fluorescence of the OVA-sensitized and challenged WT
mice were only slightly elevated (Fig. 2 B, frame 3). How-
ever, COX-2 immunofluorescence was strikingly intense
in the bronchioles of OVA-sensitized and challenged UG-
KO mice (Fig. 2 B, frame 4). Significantly, the intensity of
COX-2 immunofluorescence in OVA-sensitized UG-KO
mice, treated with rUG before OVA challenge was mark-
edly less intense (Fig. 2 B, frame 5), suggesting that UG
suppresses allergen-induced stimulation of COX-2 gene
expression in the lungs.
PGD2 Stimulates COX-2 Gene Expression In Vitro. It
has been reported that acute antigen challenge leads to in-
creased PGD2 levels in human airways (7). Moreover, aller-
gen-induced inflammation in asthmatic airways is associ-
ated with high levels COX-2 expression (17). Further, in
DP-null mice allergen challenge do not elicit airway in-
flammation (18). The results of our present study show ele-
vated levels of PGD2 in the BALF (Table S3) and high level
of COX-2 gene expression in the lungs of OVA-sensitized
Figure 3. PGD2-stimulated COX-2 ex-
pression is mediated via DP. DP-mRNA
expression determined by RT-PCR analysis
followed by hybridization with the respective
mouse and human DP-cDNA probes (A,
inset) in BSM 2146 (lane 1) and NIH-3T3
cells (lane 2). 3H-PGD2 binding (A) to BSM
2146 ( ) and NIH-3T3 ( ) cells. Note un-
labeled PGD2 displaces bound 3H-PGD2
in a dose-dependent manner. Analysis of
COX-2 mRNA expression by real-time
quantitative RT-PCR (B). NIH-3T3 cells
were treated with DP monoclonal antibody
before treatment with PGD2. Results are
expressed as the mean of three independent
experiments   SD. Asterisks indicates sig-
nificance at P    0.05. Bar 1, untreated
control cells; bar 2, PGD2-treated cells.
Prior to PGD2 stimulation, cells were
treated with DP monoclonal antibody at
varying dilutions: bar 3, 1:5,000; bar 4,
1:1,000, and bar 5, 1:100. COX-2 protein
expression by Western blot analysis (C).
Top row: lane 1, untreated control; lane 2,
PGD2-treated cells; lane 3, cells treated with
DP monoclonal antibody at 1:5,000 dilution
(lane 3); 1:1,000 dilution (lane 4); and 1:100
dilution (lane 5). Inhibition of COX-2
protein expression in cells treated with DP
antisense s-oligonucleotide (D). Lane 1,
untreated control; lane 2, cells treated with
PGD2; lane 3, cells treated with nonspecific
s-oligo; and lane 4, cells treated with DP
antisense s-oligo before PGD2 stimulation.Mandal et al. 1323
and challenged UG-KO mice (Fig 2, A and B). Thus, we
sought to determine if there is a link between the elevated
levels of PGD2 and COX-2 gene expression. We used
three representative cell types (i.e., epithelial, smooth mus-
cle, and fibroblast cells) of the mammalian respiratory sys-
tem. These cell types were used because these cell types, in
cooperation with the immune system, orchestrate the initi-
ation and propagation of allergen-induced inflammatory
responses (25–27). We treated the cells with varying con-
centrations of PGD2 and determined COX-2 mRNA and
protein expression by Northern and Western blot analyses,
respectively. The results show that PGD2 stimulates COX-2
mRNA expression and that this stimulation is time (Fig.
2, C and D) and dose dependent (Fig. 2, E and F). The re-
sults of Western blot analyses show that PGD2 stimulates
COX-2 protein expression in both NIH-3T3 and BSM-
2146 cells (Fig. 2, G and H). Consistent with these results,
we also found that PGD2 stimulates COX-2 mRNA ex-
pression in A549 cells (not depicted). Treatment of the cells
with ethanol, used as solvent for PGD2, did not stimulate
COX-2 expression. Together, our results indicate that
PGD2 acts as a potent stimulant for COX-2 expression in
three cell types of the respiratory system.
PGD2-Stimulated COX-2 Expression is Mediated via DP.
It has been demonstrated that PGD2 mediates allergen-
induced airway inflammation via its receptor, DP (18). In this
study, we found that PGD2 stimulates COX-2 expression
in three different cell types of the respiratory system. To
understand the mechanism(s) of PGD2-stimulated COX-2
gene expression and inflammatory lipid mediator produc-
tion, we first determined DP expression and PGD2 binding
using BSM-2146 and NIH-3T3 cells. The results of semi-
quantitative RT-PCR analyses show that these cells ex-
press DP-mRNA (Fig. 3 A, inset). We also performed
competition-binding assays using 3H-PGD2 as the ligand.
The results show that 3H-PGD2 binding on these cells is
saturable, and it is displaced by nonradioactive PGD2 in a
dose-dependent manner (Fig. 3 A). Since it has been re-
ported that a chemoattractant receptor, CRTH2, also binds
PGD2 in some cell types and may transduce some of the bi-
ological effects of this eicosanoid, we tested the expression
of CRTH2-mRNA in these cells. The results show that
the CRTH2-mRNA level is virtually undetectable (not
depicted), indicating that CRTH2 is unlikely to be the
predominant pathway for PGD2 signaling in these cell
types.
Figure 4. Molecular mechanism(s) of DP signaling is
cell type specific. PGD2 stimulation of BSM-2146 cells
induces tyrosine phosphorylation of p38 (A) and p44/
42 (B), whereas in NIH-3T3 cells such treatment leads
to tyrosine phosphorylation of only p38 MAPK (C).
Moreover, p38 MAPK inhibitor, SB203580, inhibits
PGD2-induced COX-2 mRNA expression in a dose-
dependent manner (D). In BSM-2146 cells, rUG (1
 M) treatment inhibits PGD2-mediated phosphoryla-
tion of both p44/42 and p38 MAPK (E), and in
NIH-3T3 cells rUG inhibits phosphorylation of only
p38 MAPK (F).Uteroglobin Represses DP-mediated Inflammation 1324
To confirm whether PGD2-stimulated COX-2 expres-
sion is mediated via DP, we treated the NIH-3T3 cells with
DP monoclonal antibody and stimulated these cells with
PGD2. We analyzed both COX-2 mRNA and COX-2
protein expression by real-time quantitative RT-PCR and
Western blot analyses, respectively. The results show that al-
though a low level of COX-2 mRNA expression is detect-
able in PGD2-untreated control cells (Fig. 3 B, bar 1), PGD2
treatment stimulates markedly higher levels of COX-2 ex-
pression (Fig. 3 B, bar 2). In contrast, COX-2 expression in
cells treated with three different dilutions of DP monoclonal
antibody before PGD2 stimulation was significantly reduced
(Fig. 3 B, bars 3–5). Consistent with these findings, the re-
sults of Western blot analysis show that the PGD2 untreated
cells produced virtually no COX-2 protein (Fig. 3 C, top
row, lane 1); however, those treated with PGD2 markedly
stimulated COX-2 protein expression (Fig. 3 C, top row,
lane 2). In contrast, cells treated with three different dilu-
tions of DP monoclonal antibody showed a marked reduc-
tion in COX-2 protein in a dose-dependent manner (Fig. 3
C, top row, lanes 3–5). To further confirm that PGD2-stim-
ulated COX-2 expression is DP mediated, we treated the
cells with DP antisense s-oligonucleotide before PGD2
stimulation. The results show that although COX-2 protein
expression in cells without PGD2 treatment is undetectable
(Fig. 3 D, lane 1), in PGD2-treated cells (Fig. 3 D, lane 2)
and in cells treated with sense s-oligo before PGD2 stimula-
tion (Fig. 3 D, lane 3) it is readily detectable. Moreover,
marked inhibition of COX-2 protein expression was ob-
served in cells that are first treated with DP antisense s-oligo
before PGD2 treatment (Fig. 3 D, lane 4). Together, these
results provide strong evidence that the stimulation of
COX-2 expression by PGD2 is mediated via DP.
Molecular Mechanism(s) of DP-Signaling is Cell Type Specific.
Although our results demonstrate that PGD2 stimulates
COX-2 expression via DP, the molecular mechanisms of
DP signaling, until now, remained unclear. Thus, we stud-
ied the mechanism(s) of DP signaling using our in vitro ex-
perimental system. The prostanoids signal through specific
G protein–coupled receptors, and it has been reported that
many agonists of these receptors activate the MAPK path-
way (28). Thus, we analyzed the phosphorylation-depen-
dent activation of kinase pathways. We treated the cells
with PGD2 for varying lengths of time and analyzed tyro-
sine phosphorylation of MAPK by Western blot analysis us-
ing anti–phospho p38-MAPK (Tyr-182) and anti–phospho
p44/42-MAPK (Tyr-204) antibodies. PGD2 stimulates the
phosphorylation of both p38- (Fig. 4 A) and p44/42-
MAPK (Fig. 4 B) in BSM-2146 cells, whereas in NIH-3T3
cells PGD2 stimulates the phosphorylation of p38 (Fig. 4 C)
but not p44/42 MAPK (not depicted). These results indi-
cate that DP signaling is mediated via the p38 and p44/42
MAPK pathways in a cell type–specific manner. We further
confirmed the above findings by analyzing the effects of
specific p38 MAPK inhibitor, SB203580, at varying con-
centrations, on PGD2-induced COX-2 expression in NIH-
3T3 cells. The results show that SB203580 inhibits PGD2-
induced COX-2 mRNA expression in a dose-dependent
manner (Fig. 4 D). Most importantly, we found that rUG
treatment inhibits PGD2-stimulated tyrosine phosphoryla-
tion of both p38 and p44/42 MAPK in BSM-2146 (Fig. 4
E) and p38 MAPK in NIH-3T3 cells (Fig. 4 F).
DP Signaling Is Mediated via p38, p44/42, and PKC-acti-
vating NF- B and COX-2 Expression. To determine the
possible involvement of other kinase pathways in DP sig-
naling, we treated these cells with PGD2 in the absence and
presence of highly selective inhibitors of PKC (BMIII), p38
(SB203580), and p44/42 MAPK (PD98059), and deter-
mined COX-2 mRNA expression by Northern blot analy-
sis. We found that in BSM-2146 cells the inhibitors of all
three kinases suppressed PGD2-mediated stimulation of
COX-2 mRNA expression at varying degrees (Fig. 5 A),
suggesting that in these cells DP signaling is mediated via
activation of p38 and p44/42 MAPK and PKC pathways.
In contrast, PGD2-mediated stimulation of COX-2 expres-
sion in NIH-3T3 cells was inhibited only by p38 MAPK
inhibitor, SB203580 (Fig. 5 B), whereas in A549 cells only
the PKC-specific inhibitor (BMIII) suppressed such stimu-
lation (not depicted).
Current evidence indicates that both MAPK and PKC
are capable of activating NF- B, a pivotal transcription fac-
tor that regulates many genes that are critical for inflamma-
tion and immunity (29). Therefore, we first examined the
effects of specific inhibitors of NF- B, pyrrolidine dithio-
carbamate and NF- B SN50, on PGD2-stimulated COX-2
mRNA expression. These agents are effective in inhibiting
PGD2-mediated stimulation of COX-2 mRNA expression
in both BSM-2146 (Fig. 5 C) and NIH-3T3 (Fig. 5 D) cells
in a dose-dependent manner. These results suggest that DP-
mediated COX-2 expression requires NF- B activation. To
determine whether the aforementioned kinase inhibitors in-
hibit DNA binding activity of NF- B, we also conducted
EMSAs to determine the effect of SB203580, PD98059,
and BMIII on PGD2-stimulated NF- B activation in both
NIH-3T3 and BSM-2146 cells. The results show that al-
though in BSM-2146 cells all three inhibitors suppress the
binding of NF- B probe (Fig. 5 E), in NIH3T3 cells only
SB203580 was inhibitory (Fig. 5 F). Further, to confirm
that NF- B activation is required for the PGD2-stimulated
COX-2 expression, we performed the COX-2 promoter-
reporter (luciferase) activation assays by transfecting NIH-
3T3 cells with reporter constructs, pGL2-COX2WT or
pGL2-COX2MU (30), containing WT and mutant NF- B
binding site, respectively. Cells transfected with the vector
alone served as controls. The results show that although
PGD2 stimulates luciferase activity in the cells transfected
with the pGL2-COX2WT construct, cells transfected with
pGL-COX2MU construct had markedly reduced level of
luciferase activity (Supplemental Materials and Methods and
Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20031666/DC1). Together, these results indicate that
DP signaling is mediated via p38 and p44/42 MAPK and
PKC pathways in a cell type–specific manner leading to
NF- B activation, required for COX-2 gene expression.Mandal et al. 1325
UG Inhibits PGD2-Stimulated COX-2 Gene Expression In
Vitro. We have shown that UG counteracts allergen-
induced COX-2 gene expression in OVA-challenged al-
lergic model of UG-KO mice (see the UG Inhibits Allergen-
induced Stimulation…). Since OVA induces elevated levels
of PGD2 in BALF, we determined if UG inhibits PGD2-
mediated stimulation of COX-2 expression in vitro. We
treated BSM-2146 and NIH-3T3 cells with PGD2 in the
presence and absence of varying concentrations of UG and
determined COX-2 mRNA expression by Northern blot
analysis. We found that in both BSM-2146 (Fig. 6 A) and
NIH-3T3 (Fig. 6 B) cells UG inhibits PGD2-induced
COX-2 mRNA expression in a dose-dependent manner.
Myoglobin (MG), a nonspecific control does not inhibit
PGD2-stimulated COX-2 expression. Together, these re-
sults suggest that UG specifically inhibits PGD2-mediated
COX-2 expression.
UG Inhibits COX-2 Expression by Suppressing PGD2-stim-
ulated NF- B Activation. It has been reported that the
COX-2 gene expression is regulated by at least three ma-
jor nuclear factors (i.e., NF- B, NF-IL6, and AP-1) lo-
cated in the 5  regulatory region of this gene. Since our
results show that PGD2-stimulated COX-2 expression is
mediated via NF- B activation, we determined whether
UG treatment of the cells blocks PGD2-mediated activa-
tion of this transcription factor. We performed EMSAs to
identify and confirm the nuclear factor(s) specifically acti-
vated by PGD2 treatment of the cells leading to COX-2
expression. The results show that among the three major
nuclear factors PGD2 specifically activates NF- B (Fig. 6
C) in a time-dependent manner (Fig. 6 D). To determine
whether UG blocks PGD2-induced NF- B activation,
we performed EMSA using nuclear extracts from NIH-
3T3 and BSM-2146 cells treated with PGD2 in the pres-
ence and absence of UG. The results show that UG spe-
cifically inhibits DP-mediated activation of NF- B in
both BSM-2146 (Fig. 6 E) and NIH-3T3 (Fig. 6 F) cells.
Our results provide strong evidence that UG inhibits
PGD2 receptor–mediated inflammation by blocking the
activation of NF- B.
Figure 5. Inhibitors of p38, p44/42, and PKC suppresses
DP-mediated NF- B activation and COX-2 expression.
Expression of COX-2–mRNA in BSM-2146 (A) and in
NIH-3T3 (B) cells in the absence or presence of inhibitors
of p38 MAPK (SB203580, 10  M), p44/42 MAPK
(PD98059, 20  M), or PKC (BM III, 10  M). Dose–response
of NF- BSN50  and PTDC on PGD2-stimulated COX-2
mRNA expression in BSM-2146 (C) and NIH-3T3 (D) cells.
The effect of these inhibitors on NF- B binding in BSM-
2146 (E) and NIH-3T3 (F).Uteroglobin Represses DP-mediated Inflammation 1326
Discussion
Allergen-induced hypersensitivity and inflammation represent
a growing public health problem in the industrialized world,
affecting nearly 30% of the population  30 yr of age (31).
The molecular mechanisms that underlie the pathophysiology
of these conditions are poorly understood. In the present
study, we uncovered several new and important aspects of al-
lergen-induced inflammatory response and a possible innate
homeostatic mechanism that represses such responses. More
specifically, we found that: (a) in response to allergen (OVA)
sensitization and challenge, UG-KO mice manifest signifi-
cantly elevated levels of COX-2 gene expression in the lungs
compared with that of the WT littermates; (b) in response to
OVA sensitization and challenge, these mice also express ele-
vated levels of eotaxin and Th2 cytokines, such as IL-4, IL-5,
and IL-13, manifesting a markedly increased eosinophil infil-
tration in the lungs; and (c) most importantly, rUG treatment
of the OVA-sensitized UG-KO mice before OVA challenge
abrogates these allergic inflammatory responses. Using an in
vitro system, we further demonstrate that (a) PGD2 mediates
COX-2 expression specifically via its receptor, DP, and (b)
DP signaling is mediated via p38 MAPK, p44/42 MAPK, or
PKC in a cell type–specific manner activating NF- B re-
quired for the expression of COX-2, an agonist-inducible
enzyme critical for the production of inflammatory lipid me-
Figure 6. UG inhibits DP-medi-
ated NF- B activation and COX-2
expression. Expression of COX-2
mRNA in BSM 2146 (A) and NIH-
3T3 cells (B). Cells were treated
with PGD2 in the presence of rUG
(0–200 nM) or MG (200 nM). Note
that rUG inhibits DP-mediated
COX-2 mRNA expression in a
dose-dependent manner in both
BSM-2146 (A) and NIH-3T3 (B),
whereas MG has no such inhibitory
effects (A and B, last lanes). EMSA
using  32P-labeled double stranded
NF- B, NF-IL6, and AP-1 oligo
probes in the absence and presence
of respective double stranded com-
petitor unlabeled oligo, demonstrat-
ing the effect of DP signaling on the
activation of NF- B in NIH-3T3
(C) cells. This activation of NF- B
by PGD2 is time dependent (D).
EMSA demonstrating the effect of
DP signaling on the activation of
NF- B in BSM-2146 (E) and NIH-
3T3 (F) cells treated with PGD2 in
the absence or presence of 150 nM
purified rUG. Note rUG treatment
before the addition of PGD2 inhibits
NF- B activation in both cell types.Mandal et al. 1327
diators. Further, rUG treatment of the cells blocks PGD2-
stimulated NF- B activation and COX-2 expression.
PGD2 is an inflammatory eicosanoid released into human
airways upon acute antigen challenge (7). Moreover, human
lung and mast cells have been reported to generate PGD2 in
a calcium-dependent manner (9, 11). Our results show a
marked reduction of PGD2 levels in the BALF of OVA-
sensitized UG-KO mice that are treated with rUG before
OVA challenge. Previous reports indicate that UG is a po-
tent antichemotactic agent for monocytes and neutrophils
(32, 33). Thus, UG is likely to have similar antichemotactic
effects on eosinophils and mast cells preventing lung infiltra-
tion. Since activated mast cells secrete PGD2, rUG may re-
duce the level of this eicosanoid in the lungs of allergen-
challenged UG-KO mice by inhibiting the migration of
mast cells. Recently, using a mouse model of allergic airway
inflammation Honda et al. (13) have reported that inhala-
tion of aerosolized PGD2 by OVA-sensitized mice precipi-
tated allergic inflammatory response in the lungs. Since
acute antigen challenge stimulates PGD2 release (7) and this
prostanoid is a potent chemoattractant for human eosino-
phils (24), it is likely that UG gene is strategically expressed
in the airway epithelia to protect this vital organ from alle-
gen-induced, PGD2-mediated eosinophil infiltration.
Although it has been reported that PGD2 mediates aller-
gic inflammation via its receptor, DP, the molecular mech-
anism(s) of DP signaling and how it mediates inflammatory
response, until now, remained unclear. Since one of the
major goals of this study was to understand the mecha-
nism(s) by which UG prevents the allergen-induced in-
flammatory responses, we determined whether UG plays
any role in down-regulating DP signaling and PGD2-stim-
ulated COX-2 expression. We first uncovered that DP sig-
naling is mediated via p38 MAPK, P44/42 MAPK, and
PKC in a cell type–specific manner leading to the activa-
tion of NF- B and subsequent stimulation of COX-2 gene
expression. To our knowledge, this is the first report delin-
eating the mechanism of DP-mediated activation of NF-
 B and consequent stimulation of COX-2 gene expression
in three different cell types. Most importantly, our results
show that rUG inhibits DP-mediated NF- B activation
and OVA-induced stimulation of PGD2 levels in BALF. In
addition, rUG inhibits OVA-induced expression of eo-
taxin, several Th2 cytokines (i.e., IL-4, IL-5, IL-13), and
COX-2, a critical enzyme for the production of inflamma-
tory lipid mediators. Cytokines such as IL-4, IL-5, and IL-
13 are capable of inducing IgE production and activation of
mast cells and eosinophils (34, 35). Our results show that
the level of these cytokines is markedly reduced by rUG
treatment of OVA-sensitized UG-KO mice before OVA
challenge. IL-13 has been suggested to play a critical regu-
latory role in mediating allergic inflammation (36–38) and
has been reported to stimulate UG gene expression in rat
lungs (23). Therefore, UG may have a homeostatic role in
down-regulating allergic inflammatory response. Our results
indicate that UG suppresses allergic inflammatory response
not only by inhibiting COX-2 expression and reduction of
PGD2 levels in the BALF but also by inhibiting the pro-
duction of proinflammatory cytokines and eotaxin.
Structural studies have delineated that UG is a ho-
modimeric protein in which the identical 70-amino acid
subunits are joined in antiparallel orientation by two inter-
chain disulfide bonds forming a central hydrophobic cavity
(3, 4). Previous reports have indicated that UG binds hy-
drophobic ligands such as progesterone (39) and retinol
(40), raising the possibility that it may also bind and possi-
bly sequester other hydrophobic ligands such as PGD2. We
have conducted molecular modeling studies using the crys-
tallographic coordinates of human rUG (24), and we have
shown that the structural features of UG readily allow
docking of PGD2 into its central hydrophobic cavity (Sup-
plemental Materials and Methods and Fig. S2, available
at http://www.jem.org/cgi/content/full/jem.20031666/
DC1). Consistent with this finding, the results of our ex-
periment show that when 3H-PGD2 is incubated with rUG
a radioactive PGD2–UG complex is readily detectable by
SDS-PAGE analysis (Supplemental Materials and Methods
and Fig. S3, available at http://www.jem.org/cgi/content/
full/jem.20031666/DC1). Thus, it appears that at least one
of the mechanisms by which UG may prevent DP-medi-
ated NF- B activation and COX-2 gene expression is by
sequestering this eicosanoid into its hydrophobic cavity,
thereby suppressing the inflammatory response. Since UG
is one of the most abundant proteins constitutively ex-
pressed in the lungs ( g/ml of BALF) and our results indi-
cate that the maximum PGD2 levels in the BALF of OVA-
sensitized and -challenged WT mice are pg/ml range, the
stoichiometry appears to favor our proposed model.
PGD2 is a potent chemoattractant for eosinophils (24),
and transgenic mice in which PGD2 synthase overexpres-
sion is targeted to the lungs manifest elevated Th2 cyto-
kines and eosinophil infiltration (14). Recently, it has been
reported that aerosolized PGD2 reinforces allergen-induced
inflammatory response via macrophage-derived chemo-
kines (13). Although our results reconfirm the important
role of PGD2 in allergen-induced inflammatory response
and the critical role of UG in suppressing such response
mediated via DP signaling, these results also suggest that
UG suppresses the production of OVA-induced chemo-
kines. Our results also demonstrate that UG inhibits OVA-
induced stimulation of eosinophil infiltration in the lungs
of UG-KO mice. This observation is consistent with our
previous finding that UG inhibits chemotaxis of monocytes
and neutrophils (32, 33), although the molecular mecha-
nism(s) of this effect of UG is not yet clear. Since UG binds
to cell surface binding proteins (putative receptors) (41), fu-
ture studies may delineate whether the antichemotactic ef-
fects of UG are mediated via these binding proteins.
It has been reported that although UG gene expression
in the airway epithelia is constitutive, its expression is fur-
ther augmented by glucocorticoids (42), the most effective
drug currently available for the treatment of airway inflam-
mation. Although the administration of nonsteroidal anti-
inflammatory drugs, which are known to inhibit bothUteroglobin Represses DP-mediated Inflammation 1328
COX-1 and COX-2 enzymes (16), may have catastrophic
consequences in  10% of the adults with asthma, it has
been reported that selective COX-2 inhibitors such as rofe-
coxib and celecoxib do not manifest such adverse reactions
(43, 44). Thus, the commonly available nonsteroidal anti-
inflammatory drugs may have effects in addition to the
COX-2 inhibitory activity that causes the adverse compli-
cations in asthmatic patients. On the other hand, glucocor-
ticoids, which inhibit COX-2 gene expression and reduce
prostaglandin levels (45), remain the mainstay of current
treatment for airway inflammation in asthma, which often
has an allergic component. Although the mechanism(s) of
antiinflammatory effects of glucocorticoids is still the sub-
ject of intense investigation, a recent study has elegantly
demonstrated that targeted disruption of a glucocorticoid-
inducible gene, lipocortin-1 (annexin-1) (46), in mice
causes increased COX-2 expression and manifests an exag-
gerated inflammatory response (47). These results are con-
sistent with those observed in our UG-KO mice.
We have reported previously that UG-deficient mice
manifest abnormal deposition of fibronectin and IgA in the
kidney glomeruli (48), reminiscent of human IgA nephrop-
athy. Further, the results of our present investigation to-
gether with those of our previous study (6) indicate that
UG-KO mice are susceptible to developing exaggerated
inflammatory response to allergen challenge that is abro-
gated by rUG treatment. This may explain a long-standing
unexplained linkage between inflammation in the respira-
tory system with disease pathology in the renal system.
Several reports have documented that inflammatory lung
diseases are associated with abnormal deposition of IgA and
extracellular matrix proteins, such as fibronectin, in the re-
nal glomeruli (49–53) as we have reported in UG-KO
mice (5). These observations, together with the facts that
(a) chronic airway inflammation markedly suppresses UG
production (53) and (b) the UG-KO mice (5) develop IgA
nephropathy (48) may further support the notion that pul-
monary inflammation and renal pathologies are causally re-
lated. Our results demonstrate the importance of UG and
perhaps of other proteins with similar properties in main-
taining homeostasis in two different vital organs, the lungs
and the kidneys.
The respiratory system and the renal system communicate
with the external environment providing a portal of entry
for microorganisms and other foreign antigens and allergens.
During the last decade, tremendous progress has been made
in delineating the innate defense mechanisms that exist
against microbial pathogens (54). However, even after the
pathogens are destroyed by the innate microbial defense sys-
tem, the respiratory system must also cope with inadvertent
stimulation of inflammation induced by antigens associated
with these pathogens. The mechanism(s) by which the
majority of the individuals avert inadvertent stimulation
of inflammatory response despite constant exposure to for-
eign antigens remains a mystery. It is tempting to speculate
that UG is strategically expressed in organs that communi-
cate with the external environment and provide protection
against allergen-induced stimulation of the inflammatory re-
sponse. Further understanding of the molecular mechanisms
of action of UG and other related proteins may allow the
development of novel therapeutic approaches to at least
some allergic and inflammatory disorders.
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